

To be published in Part-I Section I of the Gazette of India Extraordinary

F. No. 6/59/2026-DGTR
Government of India
Ministry of Commerce & Industry
Department of Commerce
Directorate General of Trade Remedies
4th Floor, Jeevan Tara Building,
5, Parliament Street, New Delhi- 110001

Dated: 24th September 2026

SETU Case ID – AD/OI/060/2026

INITIATION NOTIFICATION

Subject: Initiation of an anti-dumping investigation concerning imports of "Amoxycillin Trihydrate originating in or exported from China PR".

1. **F. No. 6/59/2026-DGTR:** Having regard to the Customs Tariff Act, 1975 as amended from time to time (hereinafter referred to as the "Act") and the Customs Tariff (Identification, Assessment and Collection of Anti-dumping duty on Dumped Articles for Determination of Injury) Rules, 1995 as amended from time to time (hereinafter referred to as the "Rules" or the "Anti-dumping Rules"), Apitoria Pharma Private Limited (hereinafter also referred to as the "applicant") has filed an application before the Designated Authority (hereinafter referred to as the "Authority"), for initiation of an anti-dumping investigation concerning imports of "**Amoxycillin Trihydrate**" (hereinafter referred to as "subject good" or "product under consideration" or "PUC").
2. The present Application sought anti-dumping investigation concerning imports of the subject good originating in or exported from **China PR**. Hence, the Authority has considered **China PR** as the subject country in the present investigation.
3. The applicant has alleged that dumped imports of the subject good from the subject country are causing material injury and has requested the imposition of anti-dumping duty on the imports of the subject good from the subject country.

A. PRODUCT UNDER CONSIDERATION

4. The product under consideration in the present application is '**Amoxycillin Trihydrate**'.
5. "Amoxicillin" is a semi synthetic antibiotic, with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms. Amoxicillin is used to reduce the development of drug-resistant bacteria. Amoxicillin is a broad-spectrum penicillin antibiotic mainly used to treat bacterial infections of the respiratory tract (bronchitis, pneumonia, sinusitis), ear (otitis media), throat (strep throat), urinary tract, skin, and dental infections. It's also used, in combination with other drugs, to treat H. pylori-related peptic ulcers, and sometimes given preventively before certain dental or surgical procedures.

Unit of measurement

6. The prescribed unit of measurement for the product under consideration is Metric Tonnes (MT).

Tariff classification

7. The PUC is classified under Chapter 29 of the First Schedule to the Customs Tariff Act, 1975 specifically under the sub-headings 29411030 and the product is presently imported under this HSN Code. The applicant has also alleged the imports of PUC may be made under any other heading/tariff items. However, the customs classification is indicative only and not binding on the scope of the product under consideration.
8. The Applicant has not proposed any product control numbers (PCN) methodology in its application. The parties to the present investigation may provide their comments on the scope of PUC and propose product control numbers (PCN) methodology, if any, within 15 days of circulation of the receipt of intimation of initiation of the investigation.

B. LIKE ARTICLE

9. The applicant has stated that there are no significant differences in the article produced by the applicant and exported from the subject country. The article produced by the applicant and that imported from the subject country is comparable in terms of physical and chemical characteristics, manufacturing process and technology, functions and uses, product specifications, pricing, distribution and marketing, and tariff classification of the subject good. The subject good and the article manufactured by the applicant are technically and commercially substitutable. The applicant has claimed that the consumers of the product under consideration are using the subject good and the article manufactured by the applicant interchangeably. Thus, for the purposes of initiation of the present investigation, the article produced by the applicant has been *prima facie* considered as like article to the product being imported from the subject country.

C. SUBJECT COUNTRY

10. The subject country in the present investigation is **China PR**.

D. PERIOD OF INVESTIGATION (POI)

11. The Authority has considered the period from 1st April 2025 to 31st March 2026 (12 months) as the period of investigation (POI) for the present investigation (hereinafter referred to as "POI"). The injury investigation period shall cover the period of 1st April 2022 to 31st March 2023, 1st April 2023 to 31st March 2024, 1st April 2024 to 31st March 2025 and the period of investigation.

E. DOMESTIC INDUSTRY AND STANDING

12. Rule 2(b) defines domestic industry as follows:

"domestic industry" means the domestic producers as a whole engaged in the manufacture of the like article and any activity connected therewith or those whose collective output of the said article constitutes a major proportion of the total domestic production of that article except when such producers are related to the exporters or importers of the alleged dumped article or are themselves importers thereof in such case the term domestic industry may be construed as referring to the rest of the producers"

13. The application has been filed by Apitoria Pharma Private Limited, which is a stepdown wholly owned subsidiary of Aurobindo Pharma Ltd. The applicant has submitted that they have not imported the subject good from the subject country and is not related to producers and exporters from the subject country.
14. The applicant has submitted that the applicant accounts for more than 35% of total Indian production. The application is also supported by Centrient Pharmaceuticals India Private Limited. The Applicant and the supporter together account for more than 60% of the total Indian domestic production.
15. As per the information available on record, the Authority considers that the Applicant constitutes an eligible domestic industry within the meaning of Rule 2(b) of the AD Rules and the application satisfies the requirement of Rule 5(3) of the AD Rules.

F. BASIS OF ALLEGED DUMPING

a. Normal Value for China PR

16. The applicant has claimed that China PR should be treated as a non-market economy and the normal value should be determined in terms of Rule- 7 of Annexure I of the AD Rules. The applicant has cited Para 8(2) of Annexure I of the AD Rules and has stated that the Chinese producers should be directed to demonstrate that market economy conditions prevail in the industry producing the subject good in terms of Para 8(3) of Annexure I of the AD Rules. The applicant has claimed that for China PR, normal value should be determined in accordance with Para 7 and 8 of Annexure I of the AD Rules.
17. The applicant has submitted that efforts were made to determine normal value on the basis of price or constructed value in a market economy third country. However, the applicant could not get reliable information regarding the information on price or cost in market economy in a third country. Therefore, the normal value has been constructed based on cost of production of the applicant, duly adjusted for selling, general and administrative expenses, with reasonable profit. The same has been considered for the purpose of initiation of the investigation. There is sufficient evidence claimed by the applicant with regard to Normal value of subject good in China PR.

b. Export Price

18. The Applicant has determined the export price for the subject country by considering the volume and value of imports as per its market intelligence. However, for the purpose of the determining export price of subject good from subject country, DGCI&S data has been adopted for ascertaining ex-factory export price. Adjustments on account of Ocean freight, Ocean insurance, Port expenses, Commission, Bank Charges, Credit Cost and Inland freight in the concerned subject country have been made.

c. Dumping Margin

19. The normal value and the export price have been compared at ex-factory level, which *prima facie* shows that the dumping margin is above the *de-minimis* level and is significant with respect to the product under consideration exported from the subject country. Thus, there is *prima facie* evidence that the product under consideration from the subject country is being dumped in the Indian market by the exporters from the subject country.

G. EVIDENCE OF INJURY AND CAUSAL LINK

20. The applicant has provided *prima facie* evidence with respect to the injury suffered by the domestic industry due to the dumped imports. The volume of the subject imports from the subject country has increased in absolute terms. The subject imports have had an adverse impact on the profitability parameters of the domestic industry.
21. From the foregoing, the Authority *prima facie* finds sufficient evidence of dumping of the subject good originating in or exported from the subject country, injury to the domestic industry and causal link between the alleged dumping and injury exist to justify initiation of an anti-dumping investigation in terms of Rule 5 of the Rules, to determine the existence, degree, and effect of alleged dumping and to recommend the amount of anti-dumping duty, which if levied, would be adequate to remove injury to the domestic industry.

H. INITIATION OF ANTI-DUMPING INVESTIGATION

22. On the basis of the duly substantiated written application submitted by the applicant and having reached satisfaction based on the *prima facie* evidence submitted by the applicant concerning the dumping of the product under consideration originating in or exported from the subject country, the consequential injury to the domestic industry as a result of the alleged dumping of the product under consideration and the causal link between such injury and the dumped imports, and in accordance with Section 9A of the Act read with Rule 5 of the AD Rules, the Authority, hereby, initiates an anti-dumping investigation to determine the existence, degree, and effect of the dumping with respect to the product under consideration originating in or exported from the subject country and to recommend the appropriate amount of anti-dumping duty, which if levied, would be adequate to remove the injury to the domestic industry.

I. PROCEDURE

23. The provisions stipulated in Rule 6 of the Anti-Dumping Rules shall be followed in this investigation.

J. SUBMISSION OF INFORMATION

24. All the interested parties are required to register themselves on SETU Portal (<https://setu.dgtr.gov.in>). All communications and submissions from the interested parties shall be uploaded on the SETU portal under their registered name and corresponding SETU Case ID no. No - AD/OI/060/2026. It should be ensured that the narrative part of the submission is in searchable PDF/MS-Word format and data files are in MS-Excel format.
25. The known producers/exporters in subject country, the government of subject country through its Embassy in India, and the importers and users in India who are known to be associated with the product under consideration are being informed separately to enable them to file all the relevant information within the time limits mentioned in this initiation notification. All such information must be filed in the form and manner as prescribed by this initiation notification, the Rules, and the applicable trade notices issued by the Authority.
26. Any other interested party may also make a submission relevant to the present investigation in the form and manner as prescribed by this initiation notification, the Rules, and the applicable trade notices issued by the Authority within the time limits mentioned in this initiation notification.
27. Any party making any confidential submission before the Authority is required to make a non-confidential version of the same available to the other interested parties.
28. The interested parties are further advised to keep a regular watch on the official website of the Directorate General of Trade Remedies at www.dgtr.gov.in and SETU portal (<https://setu.dgtr.gov.in>) for any updated information with respect to this investigation. Interested parties are directed to regularly visit the website of DGTR (<https://www.dgtr.gov.in/>) to stay apprised with the further developments in the subject investigation and remain informed regarding notices that may be issued from time to time regarding questionnaire formats, PCN methodology, PCN discussion/meeting schedule, notice of oral hearing, corrigendum, amendment notifications, and other such information.

K. TIME LIMIT

29. Any information relating to the present investigation should be uploaded on the SETU portal (<https://setu.dgtr.gov.in>) under their registered name and corresponding case ID – AD/OI/060/2026.
30. Both versions of each submission, the confidential version (CV) and the non-confidential version (NCV) must be uploaded in the respective designated columns within 37 days from the date on which the non-confidential version of the application filed by the domestic industry would be circulated by the Authority or transmitted to the appropriate diplomatic representative of the exporting country as per Rule 6(4) of the AD Rules, 1995. If no information is received within the stipulated time limit or the information received is incomplete, the Authority may record its findings based on the facts available on record and in accordance with the AD Rules, 1995.
31. All the interested parties are hereby advised to intimate their interest

- (including the nature of interest) in the instant matter and file their questionnaire responses within the above time limit as stipulated in this notification through SETU portal only.
32. The 15-day period to file comments on the scope of the PUC/ PCN Methodology shall run concurrently with the time limit mentioned in para 30 above of this Initiation Notification.
 33. Extension due to Modification of PUC/PCN: An extension of time by 15 days shall be granted if the Authority, through a subsequent notice, modifies the PUC, and PCN that was not previously proposed or is different from the initiation notification. This extension of 15 days shall be granted from date of such notification of modified PUC and PCN. Extension of time by 15 days stated in this paragraph is not applicable in instances where there is no change in the PUC, and PCN methodology after initiation of investigation. Requests for a further extension of time, beyond the 15-day extension (if granted), will ordinarily not be considered except in case of exceptional circumstances, in line with the Rule 6(4) of the AD Rules.
 34. Any request for an extension must be submitted by the concerned parties through the SETU portal at least one day before the original deadline specified above. Requests submitted after this time will not be considered.

L. SUBMISSION OF INFORMATION ON CONFIDENTIAL BASIS

35. Where any party to the present investigation makes confidential submissions or provides information on a confidential basis before the Authority, such party is required to simultaneously submit a non-confidential version of such information in terms of Rule 7(2) of the Rules and in accordance with the relevant trade notices issued by the Authority in this regard. Failure to adhere to the above may lead to rejection of the response/submissions.
36. The parties making any submission (including Appendices/ Annexures attached thereto), before the Authority including questionnaire responses, are required to file confidential and non-confidential versions separately.
37. Such submissions must be clearly marked as 'confidential' or 'non-confidential' at the top of each page. Any submission that has been made to the Authority without such markings shall be treated as 'non-confidential' information by the Authority, and the Authority shall be at liberty to allow other interested parties to inspect such submissions.
38. The confidential version shall contain all information which is, by nature, confidential, and/or other information, which the supplier of such information claims as confidential. For the information which is claimed to be confidential by nature, or the information on which confidentiality is claimed because of other reasons, the supplier of the information is required to provide a good cause statement along with the supplied information as to why such information cannot be disclosed.
39. The non-confidential version of the information filed by the interested parties is required to be a replica of the confidential version with the confidential information preferably indexed or blanked out (where indexation is not possible) and such information must be appropriately and adequately summarized depending upon the information on which confidentiality is claimed. The non-confidential summary must be in sufficient detail to permit a reasonable understanding of the substance of the information furnished on a confidential basis. However, in exceptional circumstances, the party submitting the confidential information may indicate that such information is

not susceptible to summary, and a statement of reasons containing a sufficient and adequate explanation as to why such summarization is not possible, must be provided to the satisfaction of the Authority.

40. The interested parties can offer their comments on the issues of confidentiality within 7 days from the date of circulation of the non-confidential version of the documents.
41. The Authority may accept or reject the request for confidentiality on examination of the nature of the information submitted. If the Authority is satisfied that the request for confidentiality is not warranted or if the supplier of the information is either unwilling to make the information public or to authorize its disclosure in generalized or summary form, it may disregard such information.
42. Any submission made without a meaningful non-confidential version thereof or a sufficient and adequate cause statement in terms of Rule 7 of the Rules, and appropriate trade notices issued by the Authority, on the confidentiality claim shall not be taken on record by the Authority.

M. INSPECTION OF PUBLIC FILE

43. All non-confidential versions of submissions made by any interested party will be accessible to other interested parties through their respective login on the SETU portal.

N. NON-COOPERATION

44. In case any interested party refuses access to and otherwise does not provide necessary information within a reasonable period or within the time stipulated by the Authority in this initiation notification, or significantly impedes the investigation, the Authority may declare such interested party as non-cooperative and record its findings based on the facts available and make such recommendations to the Central Government as it deems fit.

**Digitally signed by
Amitabh Kumar
Date: 24-09-2026
11:04:27
(Amitabh Kumar)
Designated Authority**